Code | CSB-MP884474HU |
Abbreviation | Recombinant Human CDCP1 protein, partial (Active) |
MSDS | |
Size | $138 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
The recombinant human CDCP1 protein is synthesized using a mammalian cell expression system. By incorporating the human CDCP1 gene fragment (30-667aa) fused with a C-terminus 10xHis-tag gene into a plasmid vector, the construct is introduced into mammalian cells. Subsequent cell cultivation promotes efficient protein expression. SDS-PAGE analysis confirms the protein's purity surpassing 95%, while the LAL method verifies its low endotoxin levels below 1.0 EU/ug. The protein's functional activity is demonstrated by its interaction with CDCP1 recombinant antibody (CSB-RA884474MA1HU), with the EC50 of 0.2943-0.4429 ng/mL.
CDCP1 is limitedly expressed in normal human tissues but is upregulated in most cancers, including lung cancer, pancreatic cancer, renal cell carcinoma, ovarian cancer, and hepatocellular carcinoma, playing a pivotal role in the onset, progression, and relapse of tumors. The signaling pathways regulated by CDCP1 play a crucial role in promoting cancer and mediating resistance to chemotherapy and targeted therapies. Additionally, its associated antibodies demonstrate high affinity and specificity, making it a potential new target for early cancer treatment. Therefore, the development of CDCP1 protein can contribute to clinical drug development and research related to CDCP1.
There are currently no reviews for this product.